阿尔茨海默病患者应用丙戊酸镁联合加兰他敏治疗的临床效果及安全性评估OA

Objective:To investigate the clinical effect and safety of magnesium valproate combined with galantamine hydrobromide in the treatment of patients with Alzheimer's disease(AD).Methods:One hundred patients with AD were selected and randomly divided into control group(n=50)and combined group(n=50).The control group was treated with galantamine hydrobromide,while the combined group was added with magnesium valproate on the basis of the control group.The cognition level[Alzheimer's disease assessment scale-cognitive subscale(ADAS-Cog)],daily living ability[Alzheimer's disease cooperative study-activity of daily living(ADCS-ADL)],behavioral and psychological symptoms[neuropsychiatric inventory(NPI)],biomarkers[phosphorylated Tau protein(p-Tau),amyloid β-protein 42(Aβ42),and brain-derived neurotrophic factor(BDNF)],oxidative stress indexes[superoxide dismutase(SOD),glutathione peroxidase(GSH-Px),and malondialdehyde(MDA)]and inflammatory factors[interleukin-6(IL-6),interleukin-1β(IL-1β),and tumor necrosis factor-α(TNF-α)]before and after treatment and incidence of adverse reactions were compared between the two groups.Results:After 3 months of treatment,the ADAS-Cog score[(24.33±1.97)points vs(26.69±2.18)points],NPI score[(46.57±3.56)points vs(49.67±4.06)points]and levels of serum p-Tau[(149.99±5.43)ng/L vs(186.87±5.97)ng/L],MDA[(6.14±0.47)nmol/mL vs(6.61±0.59)nmol/mL],IL-6[(3.89±0.36)pg/mL vs(4.38±0.37)pg/mL],IL-1β[(1.88±0.31)pg/mL vs(2.44±0.29)pg/mL]and TNF-α[(3.60±0.27)pg/mL vs(3.97±0.36)pg/mL]of patients in combined group were significantly lower than those in control group(all P＜0.05).While the ADCS-ADL score[(35.89±3.73)points vs(31.28±3.55)points]and levels of serum Aβ42[(371.35±18.85)pg/mL vs(359.93±17.72)pg/mL],BDNF[(14.45±1.10)ng/mL vs(13.32±1.08)ng/mL],SOD[(121.55±10.33)U/mL vs(110.32±8.87)U/mL]and GSH-Px[(92.87±7.73)U/mL vs(89.04±7.89)U/mL]were significantly higher than those in control group(all P＜0.05).During treatment,there was no statistical significance in the incidence of adverse reactions between the two groups of patients(P＞0.05).Conclusion:Magnesium valproate combined with galantamine hydrobromide can significantly enhance the cognitive function,promote the recovery of daily living ability,and relieve the behavioral and psychological symptoms in AD patients.Its mechanism may be related to the regulation of biomarker expression,reduction of oxidative stress and relief of inflammatory response,and this regimen does not increase the occurrence risk of adverse reactions,with good safety of medication.